BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...Monday.No safety concerns for uniQure’s Huntington’s treatmentA Phase I/II trial of gene therapy AMT-130 from uniQure N.V....
...DSMB review identified no significant safety concerns from the cohort’s first four patients. Shares of uniQure...
...Inc. Avrobio Inc. U.S. Food and Drug Administration (FDA) Adverum Biotechnologies Inc. Bristol Myers Squibb Co. TG Therapeutics Inc. ViiV Healthcare Ltd. FDA uniQure N.V. Astellas Bristol...
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...ARSA gene, to treat infantile and early juvenile onset forms of metachromatic leukodystrophy. Clinical hold for uniQure’s...
...dezparvovec, a gene therapy delivering the Padua variant of Factor IX, to treat hemophilia B. uniQure...
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...company Idera Pharmaceuticals Inc. (NASDAQ:IDRA) on Jan. 4, 2021 as SVP and COO. He was CEO of uniQure N.V....
...A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera Pharmaceuticals Inc. Ultimovacs A/S Genenta Science s.r.l. Omniome Inc. Humacyte Inc. uniQure N.V. Amgen...
BioCentury | Nov 21, 2020
Product Development

Nov. 20 Quick Takes: uniQure hemophilia therapy hits pivotal endpoint; plus data from Gilead in HIV, Aivita  in GBM and a setback for Poxel

...By BioCentury Staff uniQure hemophilia therapy hits co-primary Phase III endpointuniQure N.V. (NASDAQ:QURE) said gene therapy...
...at the Society for the Immunotherapy of Cancer (SITC) meeting.TARGETSmPTP - Mitochondrial permeability transition pore BC Staff uniQure Aivita...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Jörn Aldag chairman. He is CEO of Hookipa Pharma Inc. (NASDAQ:HOOK) and was CEO of uniQure N.V....
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...UniQure’s shares fell 22% on Thursday, the first trading session after the deal was announced. UniQure...
...with a market cap of about $3.1 billion (see “Latest Twist in uniQure’s Tale” ). UniQure...
...reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics Holding N.V., which dissolved its assets into uniQure...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up...
...etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible for undisclosed milestones and royalties. uniQure...
...Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck & Co. CSL Ltd. uniQure N.V....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...CMO. She was president and CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

...for Freeline’s FLT180a suggest the gene therapy could compete with more advanced gene therapies from uniQure N.V....
...B patients in trials of FLT180a, fidanacogene elaparvovec from Pfizer and Roche and AMT-061 from uniQure...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...commercial supply. Spark Therapeutics Inc. (NASDAQ:ONCE), Audentes Therapeutics Inc. (NASDAQ:BOLD), BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) and uniQure N.V....
Items per page:
1 - 10 of 175
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...Monday.No safety concerns for uniQure’s Huntington’s treatmentA Phase I/II trial of gene therapy AMT-130 from uniQure N.V....
...DSMB review identified no significant safety concerns from the cohort’s first four patients. Shares of uniQure...
...Inc. Avrobio Inc. U.S. Food and Drug Administration (FDA) Adverum Biotechnologies Inc. Bristol Myers Squibb Co. TG Therapeutics Inc. ViiV Healthcare Ltd. FDA uniQure N.V. Astellas Bristol...
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...ARSA gene, to treat infantile and early juvenile onset forms of metachromatic leukodystrophy. Clinical hold for uniQure’s...
...dezparvovec, a gene therapy delivering the Padua variant of Factor IX, to treat hemophilia B. uniQure...
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...company Idera Pharmaceuticals Inc. (NASDAQ:IDRA) on Jan. 4, 2021 as SVP and COO. He was CEO of uniQure N.V....
...A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera Pharmaceuticals Inc. Ultimovacs A/S Genenta Science s.r.l. Omniome Inc. Humacyte Inc. uniQure N.V. Amgen...
BioCentury | Nov 21, 2020
Product Development

Nov. 20 Quick Takes: uniQure hemophilia therapy hits pivotal endpoint; plus data from Gilead in HIV, Aivita  in GBM and a setback for Poxel

...By BioCentury Staff uniQure hemophilia therapy hits co-primary Phase III endpointuniQure N.V. (NASDAQ:QURE) said gene therapy...
...at the Society for the Immunotherapy of Cancer (SITC) meeting.TARGETSmPTP - Mitochondrial permeability transition pore BC Staff uniQure Aivita...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Jörn Aldag chairman. He is CEO of Hookipa Pharma Inc. (NASDAQ:HOOK) and was CEO of uniQure N.V....
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...UniQure’s shares fell 22% on Thursday, the first trading session after the deal was announced. UniQure...
...with a market cap of about $3.1 billion (see “Latest Twist in uniQure’s Tale” ). UniQure...
...reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics Holding N.V., which dissolved its assets into uniQure...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up...
...etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible for undisclosed milestones and royalties. uniQure...
...Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck & Co. CSL Ltd. uniQure N.V....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...CMO. She was president and CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

...for Freeline’s FLT180a suggest the gene therapy could compete with more advanced gene therapies from uniQure N.V....
...B patients in trials of FLT180a, fidanacogene elaparvovec from Pfizer and Roche and AMT-061 from uniQure...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...commercial supply. Spark Therapeutics Inc. (NASDAQ:ONCE), Audentes Therapeutics Inc. (NASDAQ:BOLD), BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) and uniQure N.V....
Items per page:
1 - 10 of 175